Keyphrases
Spesolimab
64%
Generalized Pustular Psoriasis
56%
Dermatological Adverse Effects
54%
Epidermal Growth Factor Receptor Inhibitors
42%
Dermatological Diseases
35%
Dermatologic Toxicity
23%
Hidradenitis Suppurativa
23%
Dermatologist
22%
Psoriasis Flare
22%
Adverse Events
17%
Retrospective Cohort Study
16%
Inhibitor Therapy
16%
Randomized Placebo-controlled Trial
15%
Immune-related Adverse Events
15%
ASCO Guidelines
15%
United States
15%
National Health Interview Survey
15%
Psoriasis
15%
NHANES
15%
Clinical Dermatology
15%
Tumor Treating Fields
15%
Cytotoxic Agents
15%
EGFR Inhibitors
15%
Toxic Epidermal Necrolysis
15%
Stevens-Johnson Syndrome
15%
Plain Language Summary
15%
Safety Events
15%
Acneiform Rash
15%
Adverse Effects
15%
Graft-versus-host Disease (GvHD)
14%
Skin Reactions
14%
Patients with Cancer
14%
Rash
13%
Multikinase Inhibitor
13%
Targeted Therapy
12%
Moderate to Severe
12%
Cancer Treatment
12%
Confidence Interval
12%
Skin Toxicity
12%
Treatment Options
12%
Oncologists
12%
Physician Global Assessment
11%
Cancer Therapy
11%
Placebo
11%
Erythema
11%
Papulopustular Eruption
10%
Corticosteroids
10%
Fever
10%
Paronychia
9%
Solid Organ Transplant Recipients
9%
Medicine and Dentistry
Dermatological Agent
100%
Adverse Event
54%
Epidermal Growth Factor Receptor Kinase Inhibitor
36%
Hidradenitis Suppurativa
31%
Exanthem
29%
Diseases
24%
Generalized Pustular Psoriasis
23%
Systematic Review
21%
Dermatology
21%
Epidermal Growth Factor Receptor
19%
Erythema
18%
Nail
17%
Transplantation
17%
Immune-Related Adverse Events
15%
Medical Dermatology
15%
Tumor Treating Fields
15%
EGFR Inhibitors
15%
Papulopustular
15%
Chemotherapy
14%
Immunity
13%
Quality of Life
12%
Cancer Therapy
12%
Cytotoxic Chemotherapy
11%
Diagnosis
11%
Skin Manifestation
11%
Skin Toxicity
11%
Side Effect
11%
Malignant Neoplasm
11%
Cancer Treatment
10%
Folliculitis
10%
Psoriasis
10%
Cytotoxic Agent
10%
Immunosuppressive Treatment
9%
Metastatic Colorectal Cancer
9%
Glioblastoma
9%
Acneiform Eruption
9%
Paronychia
9%
Retrospective Cohort Study
8%
Placebo-Controlled Study
8%
Immunosuppressive Drug
8%
Adverse Effect
8%
Prevalence
8%
Placebo
8%
T Cell
8%
Clinical Trial
8%
Chimeric Antigen Receptor T-Cell Immunotherapy
7%
Chimeric Antigen Receptor T-Cell
7%
COVID-19
7%
Onychomadesis
7%
Acne Vulgaris
7%
Pharmacology, Toxicology and Pharmaceutical Science
Pustular Psoriasis
46%
Dermatological Agent
31%
Epidermal Growth Factor Receptor
27%
Adverse Event
24%
Placebo
22%
Epidermal Growth Factor Receptor Kinase Inhibitor
19%
Malignant Neoplasm
19%
Skin Toxicity
19%
Diseases
16%
Erythema
16%
Psoriasis
16%
Toxic Epidermal Necrolysis
15%
Stevens Johnson Syndrome
15%
Clinical Study
13%
Rash
12%
Pustule
11%
Side Effect
10%
Metastatic Colorectal Cancer
9%
Folliculitis
9%
Placebo-Controlled Study
8%
Receptor
8%
Cotrimoxazole
7%
Interleukin 15
7%
Paronychia
7%
Telomerase Reverse Transcriptase
7%
Hearing Impairment
7%
Imatinib
7%
Fibroblast Growth Factor Receptor
7%
Acne
7%
Leukemia
7%
Gastrointestinal Stromal Tumor
7%
Povidone-Iodine
7%
Picolinic Acid
7%
Acne Vulgaris
7%
Acute Myeloid Leukemia
7%
Drug Intolerance
7%
Trastuzumab
7%
Arthritis
7%
Dermographism
7%
Pemphigus foliaceus
7%
Colorectal Carcinoma
7%
Mitogen Activated Protein Kinase Kinase Inhibitor
7%
Mantle Cell Lymphoma
7%
Acute Graft Versus Host Disease
7%
Cytokine
7%
Skin Defect
6%
Clinical Trial
6%
Cetuximab
5%
Panitumumab
5%
Lung Fibrosis
5%